Sarepta Therapeutics’ (SRPT) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note issued to investors on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $163.00 price target on the biotechnology company’s stock.

Other analysts have also recently issued reports about the stock. HC Wainwright restated a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Scotiabank began coverage on shares of Sarepta Therapeutics in a research note on Friday, March 7th. They set a “sector perform” rating and a $105.00 price objective for the company. Deutsche Bank Aktiengesellschaft began coverage on shares of Sarepta Therapeutics in a research note on Tuesday, February 11th. They set a “hold” rating and a $136.00 price objective for the company. Finally, Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $167.41.

Sarepta Therapeutics Stock Down 8.2 %

SRPT stock opened at $73.45 on Tuesday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 52 week low of $73.06 and a 52 week high of $173.25. The firm has a 50 day moving average of $108.20 and a 200 day moving average of $118.54. The stock has a market capitalization of $7.13 billion, a PE ratio of 58.76 and a beta of 0.79.

Insider Buying and Selling

In related news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SRPT. Manchester Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after buying an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after buying an additional 156 shares in the last quarter. Sunbelt Securities Inc. grew its holdings in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after buying an additional 232 shares in the last quarter. Huntington National Bank grew its holdings in shares of Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after buying an additional 175 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $36,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.